e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
Novel genetic markers in pathology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer
J. Fijolek, E. Wiatr, E. Rowinska-Zakrzewska, R. Langfort, T. Orlowski (Warsaw, Poland)
Source:
Annual Congress 2007 - Novel genetic markers in pathology
Session:
Novel genetic markers in pathology
Session type:
Electronic Poster Discussion
Number:
3215
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Fijolek, E. Wiatr, E. Rowinska-Zakrzewska, R. Langfort, T. Orlowski (Warsaw, Poland). p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer. Eur Respir J 2007; 30: Suppl. 51, 3215
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Imaging of complicated pneumonia: what is new?
Related content which might interest you:
Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer
Source: International Congress 2017 – Gene signatures in bronchial diseases
Year: 2017
Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
HER-2/neu oncoprotein expression in nonsmall cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance
Source: Eur Respir J 2001; 18: Suppl. 33, 230s
Year: 2001
MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002
Survivin expression in non-small cell lung cancer
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009
Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer
Source: Eur Respir J 2001; 17: 660-666
Year: 2001
Ki-67 in non-small cell lung cancer
Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease
Year: 2012
p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status
Source: Annual Congress 2011 - Epidemiology of lung cancer and screening
Year: 2011
Relation between ERCC1 expression in sputum and survival after cisplatin-based chemotherapy in non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 78s
Year: 2005
A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
Source: International Congress 2016 – Therapeutic trials in lung cancer
Year: 2016
The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer
Source: International Congress 2019 – Thoracic oncology: Treatment, diagnostic options and biology
Year: 2019
Prognostic value of p21 protein expression in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC)
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
Prognostic significance of nestin expression in patients with resected non-small cell lung cancer treated with platinum-based adjuvant chemotherapy
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept